The Primary Reason Intercept Pharmaceuticals, Inc. Was Nearly Halved in 2017

In spite of concerns regarding lead drug Ocaliva, Intercept's 46% plunge last year might offer an intriguing buying opportunity.

 
More Headlines

Follow worldbiztoday on Twitter

US Stocks